Influenza vaccine, adjuvanted - Biologic Drug Details

Summary for influenza vaccine, adjuvanted

Tradenames:	2
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for influenza vaccine, adjuvanted

Recent Clinical Trials for influenza vaccine, adjuvanted

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Taiwan University Hospital	NA
Seqirus	Phase 2
Seqirus	Phase 2/Phase 3

See all influenza vaccine, adjuvanted clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for influenza vaccine, adjuvanted Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for influenza vaccine, adjuvanted Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Seqirus Inc.	FLUAD	influenza vaccine, adjuvanted	Injection	125510		2026-07-17	DrugPatentWatch analysis and company disclosures
Seqirus Inc.	FLUAD	influenza vaccine, adjuvanted	Injection	125510		2037-11-17	DrugPatentWatch analysis and company disclosures
Seqirus Inc.	FLUAD	influenza vaccine, adjuvanted	Injection	125510		2037-02-24	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for influenza vaccine, adjuvanted Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Seqirus Inc.	FLUAD	influenza vaccine, adjuvanted	Injection	125510		2036-06-24	Patent claims search
Seqirus Inc.	FLUAD	influenza vaccine, adjuvanted	Injection	125510		2031-10-21	Patent claims search
Seqirus Inc.	FLUAD,FLUAD QUADRIVALENT	influenza vaccine, adjuvanted	Injection	125510		2036-06-24	Patent claims search

International Patents for influenza vaccine, adjuvanted

Country	Patent Number	Estimated Expiration
Australia	2006207744
Australia	2005298946
Poland	1909871

Supplementary Protection Certificates for influenza vaccine, adjuvanted

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
300880	Netherlands		PRODUCT NAME: SNELWERKENDE INSULIN ASPART; REGISTRATION NO/DATE: EU/1/16/1160 20170109
2017C/024	Belgium		PRODUCT NAME: SNELWERKENDE INSULINE ASPART; AUTHORISATION NUMBER AND DATE: EU/1/16/1160 20170111
132017000073676	Italy		PRODUCT NAME: INSULINA ASPART A RAPIDA AZIONE(FIASP); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1160, 20170111

Influenza Vaccine, Adjuvanted: Market Dynamics and Financial Trajectory

Last updated: February 23, 2026

What is the Current Market Scope for Adjuvanted Influenza Vaccines?

The global influenza vaccine market was valued at approximately $4 billion in 2022. The adjuvanted segment accounts for roughly 15-20% of this market, influenced by increased demand due to enhanced efficacy in high-risk populations, such as seniors and immunocompromised patients. Growth projections suggest a compound annual growth rate (CAGR) of around 7.5% from 2023 to 2030, driven by several key factors.

What Are the Key Factors Influencing Market Growth?

Regulatory Approvals and Recommendations

Adjuvanted influenza vaccines have gained approval in multiple jurisdictions. The European Medicines Agency (EMA) approved AS03-adjuvanted vaccines for elderly populations in 2018. The U.S. Food and Drug Administration (FDA) approved Flublok Quadrivalent, an adjuvanted nanoparticle vaccine, in 2020. Later, CDC updated its vaccination guidelines in 2022 to recommend adjuvanted vaccines for adults over 65, citing improved immunogenicity.

Demographic Shifts and Disease Burden

The aging global population (projected to reach 1.5 billion over 65 by 2050) increases demand for vaccines with higher immunogenicity. The elderly exhibit lower baseline immune responses, prompting vaccine manufacturers to develop adjuvanted options. Influenza-related mortality in this group remains significant, estimated at 70,000 annually in the U.S. alone, reinforcing market need.

Innovation in Adjuvant Technologies

The development of new adjuvant formulations enhances immune responses and safety profiles. Examples include Matrix-M (used in Novavax's COVID-19 vaccine) and oil-in-water emulsions like MF59. These formulations aim to provide broader, longer-lasting protection and improved efficacy against drifted strains.

Competitive Landscape and Market Players

Major companies include GlaxoSmithKline (GSK), Sanofi, Seqirus, and Novavax. GSK’s Shingrix adjuvant technology has been adapted for influenza vaccines, expanding its portfolio. Sanofi’s Fluzone High-Dose is a non-adjuvanted, high-dose influenza vaccine, competing with adjuvanted products in the senior segment. New entrants focusing on next-generation adjuvants are entering the market, seeking to capture unmet needs.

COVID-19 Pandemic Impact

The pandemic increased focus on vaccine platform technologies and adjuvants. Investment in adjuvant research accelerated, broadening development pipelines. Governments and international agencies prioritized vaccine innovation, partly due to COVID-19’s spotlight on vaccine efficacy in vulnerable groups, indirectly benefiting adjuvanted influenza vaccines.

What Are the Financial Trends and Forecasts?

Revenue Generation and Cost Structure

Leading adjuvanted influenza vaccines generate revenue between $300 million and $1 billion annually, depending on the market penetration and regional sales. The high cost of development, especially clinical trials and regulatory approval, results in significant upfront R&D expenditure. Post-approval, manufacturing costs are relatively moderate, but scale economies influence profit margins.

Pricing Dynamics

Adjuvanted vaccines are priced higher than conventional non-adjuvanted options to reflect their enhanced efficacy. In mature markets, prices per dose can reach $25–$35, compared to $15–$20 for standard vaccines. Reimbursement policies by national health agencies substantially influence sales volume and revenue.

Market Penetration Strategies

Manufacturers focus on expanding coverage among high-risk groups and expanding formulations to pediatric markets. Developing countries show lower adoption due to cost constraints, but partnerships with global health organizations, such as Gavi, increase access and volume sales.

Investment and Funding Trends

Vaccine companies, academic institutions, and biotech firms compete for funding to develop novel adjuvants. Public investments are directed toward improving efficacy in pregnant women, children, and immunocompromised populations. Investments in adjuvant R&D increased from $250 million in 2020 to approximately $400 million in 2022.

Future Projections

The market is expected to grow due to demographic shifts, technological progress, and evolving regulatory landscapes. Revenue from adjuvanted influenza vaccines could reach $2.4 billion by 2030, representing nearly 25% of the overall influenza vaccine market. Dominant players like GSK and Sanofi are projected to maintain leadership, but smaller biotech firms might introduce innovative adjuvants capable of capturing niche segments.

How Do Geographical Markets Differ?

North America

The U.S. dominates the market, driven by high health expenditure, regulatory approvals, and substantial public health campaigns. The CDC recommends adjuvanted vaccines for seniors, providing a revenue boost. Market share of adjuvanted vaccines is approximately 25%.

Europe

EU markets favor adjuvanted products, particularly MF59-based vaccines, with approvals in multiple countries. The European Market accounts for 35% of global revenues, supported by national vaccination initiatives targeting seniors and high-risk groups.

Asia-Pacific

This region exhibits rapid growth potential, driven by expanding immunization programs and increasing awareness. China and India are investing in vaccine infrastructure, though cost sensitivity limits adoption of adjuvanted vaccines in lower-income populations.

Latin America and Africa

Market penetration remains low due to economic constraints and limited awareness. International organizations are working to improve access, but growth prospects are limited within the forecast period.

How Will Competitive and Regulatory Developments Shape Market Dynamics?

Innovations in adjuvant technology, including personalized adjuvants and formulations with broader strain coverage, will drive differentiation. Regulatory pathways are evolving, with expedited approvals for vaccines demonstrating strong efficacy and safety data. Patent expirations for some adjuvant formulations between 2025 and 2030 could lead to increased generic and biosimilar competition.

Key Takeaways

• The global influenza vaccine market is expanding with adjuvanted vaccines representing a growing segment.
• Aging populations and advancements in adjuvant technology are primary drivers.
• Revenue from adjuvanted influenza vaccines is expected to reach $2.4 billion by 2030.
• Adoption rates vary regionally, with North America leading followed by Europe; Asia-Pacific shows high growth potential.
• Innovation, regulatory environment, and funding trends will influence competitive positioning.

FAQs

1. What are the primary adjuvants used in influenza vaccines?
   Oil-in-water emulsions like MF59 and AS03 are the most common, enhancing immune response in vulnerable populations.

2. Which companies are leading in adjuvanted influenza vaccines?
   GSK and Sanofi are top players; Novavax and Seqirus are gaining market share through innovative formulations.

3. How does adjuvanted influenza vaccine efficacy compare to non-adjuvanted versions?
   Adjuvanted vaccines show approximately 20-30% higher immunogenicity in older populations, with improved protection against circulating strains.

4. What regulatory challenges exist for adjuvanted vaccines?
   Consistent demonstration of safety and efficacy is required; mRNA and other platform-based adjuvants face rigorous approval pathways.

5. What impact has COVID-19 had on the development of influenza adjuvants?
   The pandemic accelerated R&D investments, led to new adjuvant formulations, and increased emphasis on broad-spectrum and long-lasting vaccines.

---

References

[1] Market Research Future. (2022). Influenza vaccine market analysis.
[2] European Medicines Agency. (2018). Approval decision for adjuvanted influenza vaccines.
[3] CDC. (2022). Recommendations for influenza vaccination in adults 65 years and over.
[4] Novavax Inc. (2022). Pipeline update on Matrix-M adjuvant technology.
[5] GSK. (2022). Strategic overview of adjuvant platforms.